A novel mAb broadly neutralizes SARS‐CoV‐2 VOCs in vitro and in vivo, including the Omicron variants

Qiuqi Kan,Xian Lin,Tuofan Li,Xianliang Ke,Xiaoqin Jian,Lidan Hou,Wenyuan Zhang,Zhimin Wan,Quan Xie,Hongxia Shao,Lilin Ye,Jianqiang Ye,Aijian Qin,Zhong Zou,Quanjiao Chen

DOI: https://doi.org/10.1002/jmv.28657

IF: 20.693

2023-03-15

Journal of Medical Virology

Abstract:Novel immune escape variants have emerged as SARS‐CoV‐2 continues to spread worldwide. Many of the variants cause breakthrough infections in vaccinated populations, posing great challenges to current antiviral strategies targeting the immunodominance of the receptor‐binding domain within the spike protein. Here, we found that a novel broadly neutralizing monoclonal antibody (mAb), G5, provided efficient protection against SARS‐CoV‐2 variants of concern (VOCs) in vitro and in vivo. A single dose of mAb G5 could significantly inhibit the viral burden in mice challenged with the mouse‐adapted SARS‐CoV‐2 or SARS‐CoV‐2 Omicron BA.1 variant, as well as the body weight loss and cytokine release induced by mouse‐adapted SARS‐CoV‐2. The refined epitope recognized by mAb G5 was identified as 1148FKEELDKYF1156 in the stem helix of subunit S2. In addition, a human‐mouse chimeric mAb was generated based on the VH and VL genes of mAb G5. Our study provides a broad antibody drug candidate against SARS‐CoV‐2 VOCs and reveals a novel target for developing pan‐SARS‐CoV‐2 vaccines. This article is protected by copyright. All rights reserved.

virology